XPO1 and B-cell chronic lymphocytic leukemia: Our data using a human tumor cell model and CLL patient cells with heterozygous XPO1-E571K expression support this claim, as we observed no change in proliferation potential between wt and E571K mutant cells upon treatment with these molecules.